Should you launch an app? Or just a web page? This consultant weighs in with his advice. Photo courtesy of Slalom

One of the biggest decisions you'll have to make as an entrepreneur is whether you should host your product or service on the web, via an app, or through a webapp. In this quick guide, I'll go over a few tips to help you narrow down the options and make an informed decision.

First, allow me to explain each of these terms. In this context, I am assuming your big idea is either a product or service which your customer base will consume in a digital format. The question is, do you deliver your product or service via a regular webpage (web), does it require robust native application functionality (app), or can it be a hybrid model where the app runs on browser (webapp).

Certainly, if you can sell your product or services through a simple online store, then the debate is over: you should just web. If you are just selling a new gadget, for example, you don't need an app nor a webapp. E-Commerce has come such a long way that a simple webpage will suffice.

However, if that is not your situation, then here's three main considerations to help you decide between building an app or a webapp.

Native hardware required

If your product or service will use a hardware component from your audience's mobile device or tablet, such as the GPS, the Camera, the Microphone, or the Gyroscope, then you should heavily lean towards building a native app.

There are web frameworks that will allow you to gain access to a devices' camera or GPS via a webapp, but none are as stable, reliable, or robust as using a native app framework.

The question then becomes, what operating system do you develop your native app in: Apple's iOS, Google's Android, Microsoft's Windows, other or all of them?

Keep in mind there are platforms – such as Xamarin – that enable you to develop in multiple native app ecosystems simultaneously, however, deciding the platform(s) will affect your timeline, budget and audience reach. Also know that if your product or service can or should be accessible offline, then that reinforces your native app decision and eliminates a webapp given they require connectivity to run on a browser.

Universal adoption expected

In contrast, if you are looking to sign-up a broad audience then you should lean towards building a webapp.

All devices, whether mobile, tablets or laptops, have sophisticated and modern web browsers that can easily run webapps. Therefore, if you don't want to worry about deciding between different platforms, then by building a universal webapp that is compatible with all popular browsers all your users will have immediate access.

This route also bypasses all the requirements you must meet and the policies you must comply with to publish your native app to communities such as Apple's App Store or Google Play.

Even better you can update and maintain your webapp at your own pace, not having to rely on Apple's or Google's approval and publish/update schedules.

Investment tolerance 

Now, if you gathered major seed funding or hit it big in a series A round giving you a higher upfront investment tolerance, then I'd advise you to go the native app route.

The aforementioned Apple and Google native app marketplaces, albeit strict, offer amazing features that you would not be able to leverage going the webapp route. Your customer experience will almost certainly be higher going native app, which will increase your ROI, promote repeat subscribers and overall success.

But this route will be more expensive than webapp, especially if you do decide to offer it on multiple major platforms. Hence, if you have the budget, go for it and launch natively. If your investment tolerance is more reserved, then start with a webapp, and simply iterate until you are forced to go native.

Table Description automatically generated

This quick guide is by no means an exhaustive list of considerations. Product development has a million intricacies that will dictate – and sometimes demand – a specific route to market. Yet, if you ask yourself a few of the questions I laid out, you will be able to make an informed decision guiding your commercialization strategy as you kick off your startup journey.

------

Alfredo Arvide is a senior principal within product engineering at Slalom Consulting in Houston, where he helps clients tackle their most complex business challenges by applying innovative technology solutions.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from eaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in the HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”